| Literature DB >> 33800906 |
Mahmoud M Abouelfetouh1,2, Lingling Liu1, Eman Salah3,4, Rui Sun1, Sha Nan1, Mingxing Ding1, Yi Ding1.
Abstract
Goats have been used as animal models in research and are increasingly kept as companion animals. However, information about effective anesthetic drugs is scarce in this species. The objective of this study was to evaluate the effect of xylazine premedication on alfaxalone induction. Twelve clinically healthy goats weighing 18.5 ± 2 kg were randomly assigned to two groups. Induction was performed with alfaxalone alone intravenously (ALF group) or with xylazine premedication before alfaxalone administration (XYL-ALF group). The quality of induction was scored, induction doses of alfaxalone were determined, and cardiorespiratory parameters and nociceptive thresholds were measured before any treatment(s) (baseline) and at 5, 15, 25 and 35 min after alfaxalone administration. The mean dose of alfaxalone required for induction in the ALF group was greater than that in the XYL-ALF group (p < 0.001). There were no significant changes in diastolic arterial pressure (DAP), mean arterial pressure (MAP) or systolic arterial pressure (SAP) compared to baseline in either group, while hemoglobin oxygen saturation (SpO2) was lower from 5 to 25 min (p < 0.5) in the XYL-ALF group. The nociceptive threshold was significantly higher at 5 min in the XYL-ALF group than in the ALF group (p = 0.0417). Xylazine premedication reduced the required dose of alfaxalone for anesthetic induction and produced better antinociception than alfaxalone alone. In addition, the combination of xylazine and alfaxalone allowed for successful induction; however, oxygen supplementation is necessary to counteract xylazine-associated hypoxemia.Entities:
Keywords: alfaxalone; cardiorespiratory parameters; goats; induction; xylazine
Year: 2021 PMID: 33800906 PMCID: PMC8000074 DOI: 10.3390/ani11030723
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Figure 1Study timeline illustrating the time of anesthetic induction with IV alfaxalone alone (ALF group) (n = 6) and with alfaxalone following IV xylazine administration (XYL-ALF) (n = 6). The data collection time points were at baseline and at 5, 15, 25 and 35 min after alfaxalone. The pedal withdrawal reflex and end tidal carbon dioxide (PE’ CO2) were recorded only at 5 min after alfaxalone administration (black arrows).
Dose requirements and quality of anesthetic induction with IV alfaxalone alone (ALF group) or with xylazine (0.05 mg/kg bw; IV) and alfaxalone (XYL-ALF group) in goats.
| ALF Group | XYL-ALF Group | ||
|---|---|---|---|
| Induction dose (mg/kg bw) | 4.0 ± 0.30 | 2.3 ± 0.25 * | |
| Induction score | 1(0–1) | 0.5(0–1) | |
| Time to extubation (min) | 6.6 ±1.9 | 9.4 ± 3.2 |
Data are expressed as the median and range (scores), mean ± SD (doses and times). * Significant difference between the two groups (p < 0.05).
Cardiorespiratory variables and rectal temperature measured in goats at baseline and at 5, 15, 25 and 35 min after alfaxalone administration in the ALF group (4.0 ± 0.30 mg/kg bw; IV) (n = 6) and the XYL-ALF group (2.3 ± 0.25 mg/kg bw; IV) (n = 6).
| Parameter | Group | Baseline | (5) | (15) | (25) | (35) |
|---|---|---|---|---|---|---|
| HR | ALF | 103 ± 10 | 140 ± 17 * | 138 ± 16 * | 124 ± 13.3 | 117 ± 14.4 |
| XYL-ALF | 97 ± 17.2 | 118 ± 26 * | 98 ± 10.2 † | 98 ± 23 † | 94 ± 14 † | |
| SAP | ALF | 114 ± 10 | 124 ± 7 | 108 ± 12 | 111 ± 8 | 113 ± 17 |
| MAP | ALF | 87 ± 7.9 | 93 ± 6 | 83 ± 9.7 | 85 ± 14 | 79 ± 18 |
| XYL-ALF | 82 ± 10 | 68 ± 13.5 † | 70 ± 8 † | 76 ± 13 | 73 ± 9.6 | |
| DAP | ALF | 70 ± 12 | 76 ± 8 | 66 ± 9 | 72 ± 16 | 62 ± 15 |
| DAP | ALF | 70 ± 12 | 76 ± 8 | 66 ± 9 | 72 ± 16 | 62 ± 15 |
| ALF | 20 ± 2.9 | 22 ± 3.8 | 21 ± 4.5 | 21 ± 9.8 | 22 ± 6.6 | |
| XYL-ALF | 23 ± 6.8 | 16 ± 6 | 18 ± 4.3 | 19 ± 8.5 | 16 ± 2.4 † | |
| SpO2 (%) | ALF | 95 ± 2.4 | 90 ± 1.7 | 92 ± 1.9 | 93 ± 3 | 92 ± 3.4 |
| XYL-ALF | 94 ± 2.3 | 82 ± 1.7 *† | 84 ± 2.7 †* | 87 ± 3 †* | 91 ± 2 | |
| PE’CO2 | ALF | 35 ± 1.9 | ||||
| RT | ALF | 39.4 ± 0.3 | 39 ± 0.5 * | 39 ± 0.4 * | 39.1 ± 0.4 | 39.2 ± 0.4 |
| XYL-ALF | 39.4 ± 0.2 | 40 ± 0.2 * | 38.5 ± 0.3 * | 38.4 ± 0.3 * | 38.4 ± 0.2 * |
Heart rate (HR), systolic arterial blood pressure (SAP), mean arterial pressure (MAP), diastolic arterial blood pressure (DAP), respiratory rate (fR), hemoglobin oxygen saturation (SpO2), end tidal carbon dioxide (PE’CO2) and rectal temperature (RT). Data are expressed as the mean ± SD. † Significant difference between the two groups (p < 0.5). * Significant difference compared to baseline within the group (p < 0.5).
Echocardiographic variables measured in goats at baseline and at 5, 15, 25 and 35 min after alfaxalone administration in the ALF group (4.0 ± 0.30 mg/kg bw; IV) (n = 6) and the XYL-ALF group (2.3 ± 0.25 mg/kg bw; IV) (n = 6).
| Parameter | Group | Baseline | (5) | (15) | (25) | (35) |
|---|---|---|---|---|---|---|
| EF (%) | ALF | 76 ± 6 | 71 ± 8 | 73 ± 9 | 75 ± 7 | 76 ± 8 |
| XYL-ALF | 80 ± 6 | 84 ± 9 † | 78 ± 6 | 72 ± 9 | 81 ± 11 | |
| FS (%) | ALF | 38 ± 8 | 34 ± 6 | 36 ± 7 | 37 ± 6 | 39 ± 7 |
| XYL-ALF | 42 ± 7 | 47 ± 9 † | 39 ± 6 | 36 ± 7 | 44 ± 9 | |
| SV (mL) | ALF | 18 ± 5 | 17 ± 9 | 12 ± 9 | 16 ± 8 | 16 ± 3 |
| XYL-ALF | 19 ± 4 | 14 ± 7 | 14 ± 8 | 14 ± 2 | 18 ± 8 | |
| CO | ALF | 1.8 ± 0.5 | 2.4 ± 1.3 | 1.8 ±1.4 | 2 ± 0.9 | 2 ± 0.9 |
| XYL-ALF | 1.7 ± 0.2 | 1.6 ± 0.6 | 1.3 ± 0.7 | 1.4 ± 0.4 | 1.4 ± 0.5 | |
| CI | ALF | 2.4 ± 0.6 | 3 ± 1.5 | 2.3 ± 1.7 | 2.5 ± 1 | 2.5 ± 0.4 |
| XYL-ALF | 2.4 ± 0.3 | 2.3 ± 0.9 | 1.8 ± 1 | 1.9 ± 0.4 | 1.9 ± 0.8 |
Ejection fraction (EF), fraction shortening (FS), stroke volume (SV), cardiac output (CO) and cardiac index (CI). Data are expressed as the mean ± SD.† Significant difference between the two groups (p < 0.5).
Nociceptive threshold variables and flank muscle tone scores measured in goats at baseline and at 5, 15, 25 and 35 min after alfaxalone administration in the ALF group (4.0 ± 0.30 mg/kg bw; IV) (n = 6) and the XYL-ALF group (2.3 ± 0.25 mg/kg bw; IV) (n = 6).
| Parameter | Group | Baseline | (5) | (15) | (25) | (35) |
|---|---|---|---|---|---|---|
| Nociceptive threshold | ALF | 33 ± 14 | 43 ± 23 | 36 ± 21 | 28 ± 5 | 28 ± 3 |
| XYL-ALF | 29 ± 7 | 87 ± 52 *† | 45 ± 28 | 38 ± 21 | 35 ± 11 | |
| Flank muscle tone | ALF | 2(2) | 1 (1–2) | 2 (2–3) | 2 (2–3) | 2 (2–3) |
| Nociceptive | ALF | 2(1–2) |
Data are expressed as the mean ± SD. * Significant difference compared to baseline within the group (p < 0.5). † significant difference between the two groups (p < 0.5).
Induction quality scoring system.
| Score | Description |
|---|---|
| Smooth (0) | No signs of excitement; no palpebral blinking; may or may not be associated with minimal jaw movement during manipulation; clear laryngeal structure visualization and complete tongue flaccidity with easy intubation performed within ten seconds. |
| Fair (1) | Slight excitement; some rapid blinking, some limb movements and obvious jaw movement during manipulation; intubation is performed within 30–60 s with or without some jaw tone persistence. |
| Poor (2) | Marked excitement; muscle twitching; paddling of limbs; unable to place orotracheal tube. |
Modified from Dzikiti et al., 2014.
Pedal withdrawal response and flank muscle tone rating systems.
| Rating System | Score: Description |
|---|---|
| Pedal withdrawal reflex 1 | (3) Exaggerated response: Active withdrawal of stimulated leg with active movement of head. |
| Flank muscle tone 2 | (0): Complete relaxation to palpation with minimal or no tone palpable. |
1 Modified from Rodrigo-Mocholí et al., 2016; 2 Cui et al., 2017.